Drug class
Emtricitabine is a specific active pharmaceutical ingredient rather than an independent therapeutic drug class, belonging pharmacologically to the class of nucleoside reverse transcriptase inhibitors (NRTIs). Read more about Emtricitabine
39 drugs in this class 20 manufacturers
Emtricitabine is a specific active pharmaceutical ingredient rather than an independent therapeutic drug class, belonging pharmacologically to the class of nucleoside reverse transcriptase inhibitors (NRTIs).
As a synthetic cytidine analog, it undergoes cellular phosphorylation to an active triphosphate metabolite that competes with endogenous deoxycytidine triphosphate to inhibit retroviral reverse transcriptase, thereby causing viral DNA chain termination.
Clinically, emtricitabine is utilized in combination antiretroviral regimens for the treatment of human immunodeficiency virus type 1 (HIV-1) infection and, alongside complementary agents, for HIV-1 pre-exposure prophylaxis (PrEP).
Emtricitabine is a specific active pharmaceutical ingredient rather than an independent therapeutic drug class, belonging pharmacologically to the class of nucleoside reverse transcriptase inhibitors (NRTIs)
Emtricitabine is a specific active pharmaceutical ingredient rather than an independent therapeutic drug class, belonging pharmacologically to the class of nucleoside reverse transcriptase inhibitors (NRTIs)
As a synthetic cytidine analog, it undergoes cellular phosphorylation to an active triphosphate metabolite that competes with endogenous deoxycytidine triphosphate to inhibit retroviral reverse transcriptase, thereby causing viral DNA chain termination
Clinically, emtricitabine is utilized in combination antiretroviral regimens for the treatment of human immunodeficiency virus type 1 (HIV-1) infection and, alongside complementary agents, for HIV-1 pre-exposure prophylaxis (PrEP)
Clinically, emtricitabine is utilized in combination antiretroviral regimens for the treatment of human immunodeficiency virus type 1 (HIV-1) infection and, alongside complementary agents, for HIV-1 pre-exposure prophylaxis (PrEP)
Following a drug class requires a free Physicians Office Resource account.
